TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06258486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG injection
Description: Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Injection/Control
Description: No ICG injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy with pelvic lymph node dissection
Description: Robotic assisted prostatectomy with pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Prostatectomy with pelvic lymph node dissection
Description: Robotic assisted prostatectomy with pelvic lymph node dissection
Study: NCT06222320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesiotaping will be applied to patients in this group in addition to painkillers. Kinesiotaping is a physical therapy technique used to treat muscle pain. It is performed with kinesiotaping tapes attached to the skin. These bands are removed after 4-5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Painkillers
Description: Patients in this group will be treated with painkillers consisting of paracetamol and dexketoprofen.
Study: NCT05890534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pycnogenol®
Description: Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
Study: NCT06297733

Intervention type: OTHER
Intervention: Translating the Questionnaire into Turkish and Related Processes
Description: The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the inventory and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.

Intervention type: OTHER
Intervention: Validity
Description: The inventory will be applied by face-to-face technique and convergent validity will be evaluated. Construct validity will be evaluated through exploratory and confirmatory factor analysis. Coefficients of fit will be calculated.

Intervention type: OTHER
Intervention: Reliability
Description: The reliability of the items will be tested with Cronbach alpha. Test-retest reliability will be measured by ICC.
Study: NCT05052112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-PR-01
Description: Active arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-PR-01
Description: Active arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E- PR-02
Description: Placebo arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E- PR-02
Description: Placebo arm
Study: NCT06083324

Intervention type: OTHER
Intervention: Dose escalated resistance training
Description: All individuals will be engaging in resistance training during and/or after their cancer treatment

Intervention type: OTHER
Intervention: Dose escalated resistance training
Description: All individuals will be engaging in resistance training during and/or after their cancer treatment

Intervention type: OTHER
Intervention: Dose escalated resistance training
Description: All individuals will be engaging in resistance training during and/or after their cancer treatment

Intervention type: OTHER
Intervention: Dose escalated resistance training
Description: All individuals will be engaging in resistance training during and/or after their cancer treatment

Intervention type: OTHER
Intervention: Dose escalated resistance training
Description: All individuals will be engaging in resistance training during and/or after their cancer treatment
Study: NCT04672525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: 10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
Study: NCT05610306

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
Study: NCT06053957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: early mobilization program
Study: NCT03361189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed loop stimulation
Description: Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop stimulation
Description: Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard rate response
Description: Standard rate response is an algorithm to increase heartrate based on movement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard rate response
Description: Standard rate response is an algorithm to increase heartrate based on movement
Study: NCT05799001

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dance therapy
Description: Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance therapy
Description: Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer.
Study: NCT05544305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Home Based Care pathway
Description: The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.
Study: NCT06428656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotics supplementation
Description: The participants will consume one capsule of postbiotics supplement per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: The participants will consume one capsule of placebo per day
Study: NCT05749237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory exercises
Description: respiratory exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: relaxation exercises
Description: relaxation exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: relaxation exercises
Description: relaxation exercises
Study: NCT05751733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
Description: Second-line TKI drugs
Study: NCT05073393

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sugar stress
Description: Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar stress
Description: Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
Study: NCT04844658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NASAFYTOL®
Description: Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FULTIUM® -D3 800
Description: Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strandard of care treatment
Description: Strandard of care treatment for Covid-19 infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strandard of care treatment
Description: Strandard of care treatment for Covid-19 infection
Study: NCT06440889

Intervention type: DEVICE
Group type: OTHER
Intervention: Bio-Ray Knee Guard
Description: Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Ray Knee Guard
Description: Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
Study: NCT04879849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-676
Description: IV infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided radiation therapy
Description: Radiation therapy.
Study: NCT06180330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic baby class
Description: The intervention will consist of exercises for infants. They will be in the water together with parents
Study: NCT04843774

Intervention type: DRUG
Intervention: SARS-COV-2 mRNA Vaccine
Description: Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
Study: NCT05175417

Intervention type: OTHER
Intervention: MRI
Description: 3 tesla (T) MRI to provide higher resolution and quality brain images.
Study: NCT06452901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progression and structured surgical training.
Description: Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
Study: NCT06452901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progression and structured surgical training.
Description: Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
Study: NCT05729126

Intervention type: OTHER
Intervention: Questionnare
Description: A questionnaire form is emailed to radiologists to get their response of their practice with hemodialysis and chronic kidney disease patients
Study: NCT04011163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPIA pump
Description: The pump is a specially designed and manufactured infusion syringe pump for intravenous analgesia. It incorporates the VPIA study regimen to meet the specific requirements of the clinical trial. It is intended to be used only for delivering drugs intravenously.
Study: NCT05245838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
Study: NCT04011163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
Study: NCT06378398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Two 20 mg/day omeprazole tablets taken before the first meal each day for 25-45 days.
Study: NCT05245838

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
Study: NCT06378398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Two 81 mg/day aspirin tablets taken before the first meal each day for 25-45 days.
Study: NCT05942625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10390 tablet
Description: Oral administration of specified dose of HS-10390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Oral administration of matching dose ofplacebo
Study: NCT04691154

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: L606 inhalation suspension
Description: L606 inhalation suspension, twice daily dosing
Study: NCT06376851

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-enabled quantitative coronary plaque analysis (AI-QCPA)
Description: The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-enabled quantitative coronary plaque analysis (AI-QCPA)
Description: The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.
Study: NCT05748184

Intervention type: DEVICE
Intervention: ULDCT PACS prototype
Description: The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
Study: NCT05643768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training (IMST)
Description: 30 breaths/day, 5 days/week, 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle strength training (IMST)
Description: 30 breaths/day, 5 days/week, 6 weeks
Study: NCT05195827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRM-125
Description: Antihypertensive
Study: NCT06540209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: Children will be give Bacillus clausii for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: Children will be give Saccharomyces boulardii for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc will be given to all children for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc will be given to all children for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORS
Description: ORS will be given to all children for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORS
Description: ORS will be given to all children for 5 days
Study: NCT05502900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
Study: NCT05890040

Intervention type: OTHER
Intervention: questionnaire
Description: assessment of anxiety

Intervention type: OTHER
Intervention: questionnaire
Description: assessment of anxiety
Study: NCT06420843

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FOODMAP
Description: Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOODMAP
Description: Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.
Study: NCT04823039

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample taken
Description: For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
Study: NCT05527392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Insurance Navigation Tools Program
Description: The program will be delivered via videoconferencing by a navigator over approximately a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Section 1- Insurance Plan Basics; Section 2- Your Plan in Relation to Policy; Section 3- Navigating Your Plan and Overcoming Obstacles; Section 4- Managing Care Costs; 5-Understanding Your Medical Bills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Insurance Navigation Tools Program
Description: The program will be delivered via videoconferencing by a navigator over approximately a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Section 1- Insurance Plan Basics; Section 2- Your Plan in Relation to Policy; Section 3- Navigating Your Plan and Overcoming Obstacles; Section 4- Managing Care Costs; 5-Understanding Your Medical Bills.
Study: NCT05505019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Podcast listening
Description: This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
Study: NCT06105151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119(SAD)
Description: VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119 Placebo(SAD)
Description: VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119(FE)
Description: A：4 mg VV119, following an overnight fast of at least 10 hours for Period 1; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 2; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 3; B: 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1; 4 mg VV119, following an overnight fast of at least 10 hours for Period 2; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 3; C: 4mg VV119, administered 30 minutes after the start of a standard meal for Period 1; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2;4 mg VV119, following an overnight fast of at least 10 hours for Period 3.